Brentuximab (Anti-TNFRSF8 / CD30)

Brentuximab (Anti-TNFRSF8 / CD30) is a humanized chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. The antibody-drug conjugate (ADC) Brentuximab vedotin, marketed under the brand name Adcetris, is medicine used primarily to treat certain types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). This ADC drug is a conjugate that combines a monoclonal antibody Brentuximab, linker and cytotoxic agent monomethyl auristatin E (MMAE). It targets the CD30 antigen on cancer cells, delivering the MMAE directly to these cells to help destroy them. This biosimilar antibody is used for research only. MW: 145.38 KD.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG1
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human TNFRSF8/CD30
Clone	Brentuximab biosimilar
Conjugate	Unconjugated
Purity	99%
Molecular Weight	145.38 KD
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0